OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.

Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance ...

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-T) from The Globe and Mail including charting and trades.

Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where OptiNose Inc. (NASDAQ:OPTN) ...

PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology ...

Group sales fell 4 per cent to £5.6 billion ($9.5 billion) in the second quarter, with Advair/Seretide (fluticasone propionate and salmeterol) hit harder than expected by increasing competition ...

and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.

Seretide (salmeterol xinafoate/fluticasone propionate) – sold as Advair in the US and other markets – is the top-selling inhaled beta agonist and corticosteroid combination therapy in the UK.

In addition, corticosteroid nasal sprays like fluticasone (Flonase), help reduce inflammation in the nasal passages, offering longer relief from symptoms. Decongestants: If you are suffering from ...